Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324732 | 0.78 | FFAR2 (0.59) | FFAR2MAPT | |
| SCHEMBL324106 | 0.72 | KMT2A (0.42) | KMT2AALDH1A1MAPTMEN1LMNA | |
| SCHEMBL324733 | 0.61 | FFAR2 (0.46) | FFAR2MAPT | |
| SCHEMBL6017214 | 0.61 | KMT2A (0.56) | KMT2ARAB9AALDH1A1POLBMAPT | |
| SCHEMBL4111126 | 0.60 | ALDH1A1 (0.63) | KMT2ARAB9AALDH1A1POLBMAPT | |
| SCHEMBL12774648 | 0.60 | ALDH1A1 (0.68) | KMT2AALDH1A1POLBMAPTMEN1 | |
| SCHEMBL324734 | 0.60 | KDM4E (0.44) | FFAR2KMT2AALDH1A1POLBMEN1 | |
| SCHEMBL4431335 | 0.58 | KMT2A (0.57) | KMT2ARAB9AALDH1A1POLBMAPT | |
| SCHEMBL83254 | 0.58 | HRH1 (0.54) | — | |
| SCHEMBL761217 | 0.58 | ALDH1A1 (0.63) | KMT2AALDH1A1POLBMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093246-B2 | potent deoxycytidine kinase inhibitors; O-linked pyrimidin-4-amine-based compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146571-A1 | O-LINKED PYRIMIDIN-4-AMINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE TO TREAT CANCER | DPYD, DHFR, TYMP | FFAR2 4433/4885KMT2A 1034/4885RAB9A 2342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.